HIGHLIGHTS
- who: Maru00eda del Mar Noblejas-Lu00f3pez and collaborators from the Translational Research Unit, Albacete University Hospital, Albacete, Spain have published the paper: Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer, in the Journal: (JOURNAL)
- what: The authors explore the antitumoral activity of a novel proteolysistargeting chimera (PROTAC) compound against CDK9. cell lines from different subtypes were used. The authors report the antitumoral activity of that compound in cells with acquired resistance to several anti-HER2 therapies. 4 of 17 Among all these CDKs, the authors focused on CDK9, as kinase inhibitors . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.